Table 5.
DRUG Dose | No. (%) of cases | No. (%) of controls | OR (95% CI) | OR Adg (95% CI) † |
---|---|---|---|---|
NIMESULIDE | ||||
<200 mg | 21 (11.73) | 172 (9.72) | 1.41 (0.85–2.35) | 1.55 (0.89–2.70) |
≥200 mg | 9 (5.03) | 12 (0.68) | 8.03 (3.36–9.22) | 10.69 (4.02–28.44) |
ASA | ||||
<300 mg | 21 (11.73) | 168 (9.49) | 1.35 (0.80–2.27) | 1.46 (0.82–2.58) |
≥300 mg | 10 (5.59) | 85 (4.80) | 1.22 (0.62–2.43) | 1.70 (0.81–3.54) |
KETOPROFEN | ||||
<150 mg | 10 (5.62) | 142 (8.02) | 0.67 (0.34–1.34) | 0.73 (0.35–1.54) |
≥150 mg | 8 (4.49) | 19 (1.07) | 3.29 (1.35–8.04) | 4.65 (1.33–10.00) |
IBUPROFEN | ||||
<1200 mg | 20 (11.24) | 155 (8.76) | 1.45 (0.86–2.43) | 1.71 (0.97–3.02) |
≥1200 mg | 4 (2.23) | 15 (0.85) | 2.62 (0.82–8.32) | 3.73 (1.11–12.46) |
DICLOFENAC | ||||
<100 mg | 5 (2.79) | 30 (1.69) | 1.69 (0.64–4.48) | 2.13 (0.77–5.91) |
≥100 mg | 3 (1.68) | 25 (1.41) | 1.19 (0.35–4.09) | 1.21 (0.30–4.85) |
PARACETAMOL | ||||
<3000 mg | 42 (23.46) | 265 (14.97) | 2.22 (1.48–3.15) | 2.04 (1.35–3.09) |
≥3000 mg | I26 (14.52) | I44 (2.49) | I7.80 (4.53–13.43) | I6.31 (3.56–11.20) |
See methods sections for details of adjustment